Evidence map›Paper›PMID 42503479›Full record

ArticleImmunology2026

Methionine Regulates Antitumour Function of CD8

Tian Zhao, Gillian A Carleton, Sam Preshaw, Sarah MacPherson, Madison Shiyuk, Joseph Monaghan, Jun Han, Oro Uchenunu, Robert Rottapel, Ralph J DeBerardinis and 7 more

Abstract read
In one paragraph

Article in Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Tian ZhaoSchool of Molecular Life Sciences, University of Victoria, Victoria, British Columbia, Canada.ORCID https://orcid.org/0009-0001-5715-1884
Gillian A CarletonSchool of Molecular Life Sciences, University of Victoria, Victoria, British Columbia, Canada.
Sam PreshawSchool of Molecular Life Sciences, University of Victoria, Victoria, British Columbia, Canada.
Sarah MacPhersonTrev and Joyce Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
Madison ShiyukSchool of Molecular Life Sciences, University of Victoria, Victoria, British Columbia, Canada.ORCID https://orcid.org/0009-0009-4094-4982
Joseph MonaghanCentre for Health and Environmental Mass Spectrometry, Vancouver Island University, Nanaimo, British Columbia, Canada.
Jun HanUniversity of Victoria Genome BC Proteomics Centre, University of Victoria, Victoria, British Columbia, Canada.
Oro UchenunuPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Robert RottapelPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Ralph J DeBerardinisChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Kelly M StewartAgios Pharmaceuticals, Cambridge, Massachusetts, USA.
Bo-Hyun KimSchool of Molecular Life Sciences, University of Victoria, Victoria, British Columbia, Canada.ORCID https://orcid.org/0000-0003-2595-4890
Juan AusióSchool of Molecular Life Sciences, University of Victoria, Victoria, British Columbia, Canada.
David R GoodlettSchool of Molecular Life Sciences, University of Victoria, Victoria, British Columbia, Canada.
Helena PětrošováSchool of Molecular Life Sciences, University of Victoria, Victoria, British Columbia, Canada.ORCID https://orcid.org/0009-0008-9756-7236
Kyle D DuncanCentre for Health and Environmental Mass Spectrometry, Vancouver Island University, Nanaimo, British Columbia, Canada.ORCID https://orcid.org/0000-0003-0575-0858
Julian J LumSchool of Molecular Life Sciences, University of Victoria, Victoria, British Columbia, Canada.ORCID https://orcid.org/0000-0002-5624-3541

Funding

Metabolic Regulators of Tumor Growth and ProgressionR35CA220449 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI RALPH J DEBERARDINIS · 2017 to 2026
$9.4M
Canadian Foundation for Innovation and BC Knowledge Development Fund 43810Cancer Prevention and Research Institute of Texas RP240494CIHR MOP-142351CIHR PJT-162279Genome British Columbia (GBC) and Genome Canada for The Metabolomics Innovation Centre (TMIC) and the BC Proteomics Centre 365METGenome British Columbia (GBC) and Genome Canada for The Metabolomics Innovation Centre (TMIC) and the BC Proteomics Centre 374PROGenome British Columbia (GBC) and Genome Canada for The Metabolomics Innovation Centre (TMIC) and the BC Proteomics Centre 375METHoward Hughes Medical Institute Investigator ProgrammeIRiCORMichael Smith Foundation for Health Research (MSHRBC) Scholar programme SCH-2025-04631Michael Smith Foundation for Health Research (MSHRBC) trainee fellowship RT-2024-03771Mitacs Accelerate IT39177Mitacs Accelerate IT39215Natural Sciences and Engineering Research Council of Canada RGPIN-2017-04162Natural Sciences and Engineering Research Council of Canada RGPIN-2022-03696Natural Sciences and Engineering Research Council of Canada CGS M scholarshipNCI NIH HHS R35 CA220449NCI NIH HHS R35CA220449Ovarian Cancer CanadaTerry Fox New Frontiers Program Project and the Lotte John Hecht Memorial Foundation TFRI 1125The US Department of Defense OCRP W81XWH-18-1-0264University of Victoria Graduate Awards
6 · The paper itself

Abstract

Methionine is an essential amino acid critical for T cell activation. While methionine restriction (MR) combined with immune checkpoint blockade has been shown to enhance T cell function, the impact of methionine on adoptive T cell therapies remains unknown. Here, we examined the functionality of T cells under MR and pharmaceutical inhibition of the methionine cycle (MAT2Ai), using primary T cells and a murine adoptive T cell therapy model. In vitro, transient MR or MAT2Ai treatment increased interferon gamma (IFNγ) expression in CD8

Indexed as

CD8-Positive T-LymphocytesMethioninePolyaminesAnimalsCell Line, TumorImmunotherapy, AdoptiveInterferon-gammaLymphocyte ActivationMiceMice, Inbred C57BLMice, KnockoutT-Cell ExhaustionInterferon-gammaMethioninePolyaminesadoptive cell therapycancer immunologyimmunometabolismT cell

Identifiers

PMID42503479
PMCPMC13636119

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.